HRP20240211T1 - Novi kristalni oblici tienopirimidina kao mcl-1 inhibitora - Google Patents

Novi kristalni oblici tienopirimidina kao mcl-1 inhibitora Download PDF

Info

Publication number
HRP20240211T1
HRP20240211T1 HRP20240211TT HRP20240211T HRP20240211T1 HR P20240211 T1 HRP20240211 T1 HR P20240211T1 HR P20240211T T HRP20240211T T HR P20240211TT HR P20240211 T HRP20240211 T HR P20240211T HR P20240211 T1 HRP20240211 T1 HR P20240211T1
Authority
HR
Croatia
Prior art keywords
compound
cancer
crystalline form
expressed
theta
Prior art date
Application number
HRP20240211TT
Other languages
English (en)
Croatian (hr)
Inventor
Emilie DE BAETS
Julien Auvray
Michael Lynch
Nicolas LEBLANC
Original Assignee
Les Laboratoires Servier
Vernalis (R&D) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier, Vernalis (R&D) Limited filed Critical Les Laboratoires Servier
Publication of HRP20240211T1 publication Critical patent/HRP20240211T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20240211TT 2018-12-06 2019-12-05 Novi kristalni oblici tienopirimidina kao mcl-1 inhibitora HRP20240211T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306634 2018-12-06
PCT/EP2019/083773 WO2020115183A1 (en) 2018-12-06 2019-12-05 New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them.
EP19817229.8A EP3891156B1 (en) 2018-12-06 2019-12-05 New crystalline forms of a thienopyrimidine as mcl-1 inhibitor

Publications (1)

Publication Number Publication Date
HRP20240211T1 true HRP20240211T1 (hr) 2024-04-26

Family

ID=64665802

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240211TT HRP20240211T1 (hr) 2018-12-06 2019-12-05 Novi kristalni oblici tienopirimidina kao mcl-1 inhibitora

Country Status (26)

Country Link
US (2) US12129261B2 (cg-RX-API-DMAC7.html)
EP (1) EP3891156B1 (cg-RX-API-DMAC7.html)
JP (1) JP7649241B2 (cg-RX-API-DMAC7.html)
KR (1) KR102855345B1 (cg-RX-API-DMAC7.html)
CN (1) CN113166169A (cg-RX-API-DMAC7.html)
AR (1) AR117255A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019391329B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010072A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121363A1 (cg-RX-API-DMAC7.html)
DK (1) DK3891156T3 (cg-RX-API-DMAC7.html)
EA (1) EA202191534A1 (cg-RX-API-DMAC7.html)
ES (1) ES2971258T3 (cg-RX-API-DMAC7.html)
FI (1) FI3891156T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240211T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065266T2 (cg-RX-API-DMAC7.html)
IL (1) IL283656B2 (cg-RX-API-DMAC7.html)
LT (1) LT3891156T (cg-RX-API-DMAC7.html)
MA (1) MA54379B1 (cg-RX-API-DMAC7.html)
MD (1) MD3891156T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006702A (cg-RX-API-DMAC7.html)
PL (1) PL3891156T3 (cg-RX-API-DMAC7.html)
PT (1) PT3891156T (cg-RX-API-DMAC7.html)
RS (1) RS65047B1 (cg-RX-API-DMAC7.html)
SI (1) SI3891156T1 (cg-RX-API-DMAC7.html)
TW (1) TWI905090B (cg-RX-API-DMAC7.html)
WO (1) WO2020115183A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
KR20210100148A (ko) 2021-08-13
IL283656B1 (en) 2025-06-01
TW202039511A (zh) 2020-11-01
PT3891156T (pt) 2024-01-16
AU2019391329A1 (en) 2021-07-01
MA54379A (fr) 2021-10-13
SI3891156T1 (sl) 2024-03-29
CN113166169A (zh) 2021-07-23
TWI905090B (zh) 2025-11-21
HUE065266T2 (hu) 2024-05-28
EA202191534A1 (ru) 2021-10-27
PL3891156T3 (pl) 2024-05-13
RS65047B1 (sr) 2024-02-29
JP2022511495A (ja) 2022-01-31
JP7649241B2 (ja) 2025-03-19
BR112021010072A2 (pt) 2021-08-24
WO2020115183A1 (en) 2020-06-11
LT3891156T (lt) 2023-12-27
ES2971258T3 (es) 2024-06-04
AU2019391329B2 (en) 2024-09-26
AR117255A1 (es) 2021-07-21
IL283656B2 (en) 2025-10-01
EP3891156A1 (en) 2021-10-13
US20250011337A1 (en) 2025-01-09
MD3891156T2 (ro) 2024-06-30
DK3891156T3 (da) 2024-02-19
EP3891156B1 (en) 2023-11-15
NZ776907A (en) 2025-05-02
US12129261B2 (en) 2024-10-29
MA54379B1 (fr) 2023-12-29
CA3121363A1 (en) 2020-06-11
MX2021006702A (es) 2021-07-07
US20220017533A1 (en) 2022-01-20
IL283656A (en) 2021-07-29
FI3891156T3 (fi) 2024-02-07
KR102855345B1 (ko) 2025-09-03

Similar Documents

Publication Publication Date Title
US12171739B2 (en) N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
WO2025045141A1 (en) Kras inhibitors and uses thereof
JP6322770B2 (ja) Erk阻害剤
TWI704151B (zh) Erk抑制劑
KR102061917B1 (ko) 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물
HRP20161203T1 (hr) Novi derivati tienopirimidina, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže
US20210198261A1 (en) Aurora kinase inhibitors and uses thereof
WO2025153038A1 (en) Kras inhibitors and uses thereof
ES2875360T3 (es) Derivado de piridona que tiene un grupo tetrahidropiranil metilo
US20140357622A1 (en) Crystalline forms of sodium 4--2-methoxybenzoate
CN112707905B (zh) 一种三并杂环化合物及其制备方法和用途
HRP20231533T1 (hr) Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave
EP2986300A2 (en) 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h-pyrrolo [2-,3-b]pyrazine dual itk and jak3 kinase inhibitors
AU2019344398B2 (en) Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
HRP20251507T1 (hr) Kristalna fumaratna sol od (s)-[3,4-difluoro-2-(2-fluoro-4-jodofenilamino)fenil] [3-hidroksi-3-(piperidin-2-il)azetidin-1-il]metanona
CN116507337A (zh) Atr抑制剂及其用途
HRP20230563T1 (hr) Nova sol bcl-2 inhibitora, srodni kristalni oblik, postupak za pripravu istih i farmaceutski pripravci koji ih sadrže
FI3891156T3 (fi) Mcl-1-inhibiittorin uusia kiteisiä muotoja, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
CN116134022B (zh) Atr抑制剂和其用途
JP2022511495A5 (cg-RX-API-DMAC7.html)
JP2010111702A (ja) 複素環化合物、その製造法および用途
RU2021119029A (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
NZ776907B2 (en) New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them.
RU2023135057A (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
WO2023138621A1 (en) Atr inhibitors and uses thereof